We are live on ! Find out more
GRCE

Grace Therapeutics

14 hedge funds and large institutions have $1.55M invested in Grace Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

99% more capital invested

Capital invested by funds: $778K → $1.55M (+$770K)

27% more funds holding

Funds holding: 1114 (+3)

0.15% more ownership

Funds ownership: 0.07%0.23% (+0.15%)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
3
Reduced
3
Closed
1
Calls
Puts
Net Calls
Net Calls Change

GRCE Hedge Fund Activity: Q4 2017 in Review

14 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2017, worth a combined $1.55M — up 99% from $778K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GRCE positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $784K. The largest seller was Bank of Montreal, cutting an estimated $245K.

  • 14 institutional investors held Grace Therapeutics (GRCE) as of Q4 2017, up from 11 in Q3 2017.
  • Funds reported $1.55M of Grace Therapeutics stock for Q4 2017, up 99% quarter-over-quarter.
  • 4 funds opened new Grace Therapeutics positions in Q4 2017 and 1 closed out, a net change of +3 holders.
  • The largest Grace Therapeutics buyer in Q4 2017 was Susquehanna International Group, an estimated $784K added.
  • The largest Grace Therapeutics seller in Q4 2017 was Bank of Montreal, an estimated $245K sold.

Based on aggregated 13F filings for Q4 2017.